Abstract | BACKGROUND: METHODS: RESULTS: None of the polymorphisms significantly predicted baseline FMD. Patients with the C allele of A1166C showed smaller changes in FMD in comparison with patients with the AA genotype (-0.044+/-0.439% vs. 0.386+/-0.599%; p=0.016). None of the other polymorphisms significantly influenced changes in FMD. CONCLUSIONS: The C allele of AT1R A1166C is associated with significantly lower endothelial response to statin treatment.
|
Authors | Marek Kiliszek, Beata Burzyńska, Grzegorz Styczyński, Monika Maciag, Daniel Rabczenko, Grzegorz Opolski |
Journal | Clinical chemistry and laboratory medicine
(Clin Chem Lab Med)
Vol. 45
Issue 7
Pg. 839-42
( 2007)
ISSN: 1434-6621 [Print] Germany |
PMID | 17617024
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Receptor, Angiotensin, Type 1
|
Topics |
- Adult
- Aged
- Coronary Disease
(genetics, metabolism)
- Endothelium, Vascular
(drug effects, physiology)
- Female
- Gene Frequency
- Genotype
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(metabolism, pharmacology)
- Male
- Middle Aged
- Polymorphism, Genetic
- Receptor, Angiotensin, Type 1
(genetics, metabolism)
- Vasodilation
(drug effects)
|